Social Determinants of Health Research Center, Saveh University of Medical Sciences, Saveh, Iran.
Department of Medical Laboratory Sciences, School of Para Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mol Biol Rep. 2022 Nov;49(11):10315-10325. doi: 10.1007/s11033-022-07785-4. Epub 2022 Sep 12.
Common treatments of liver disease failed to meet all the needs in this important medical field. It results in an urgent need for proper some new adjuvant therapies. Mesenchymal stem cells (MSCs) and their derivatives are promising tools in this regard. We aimed to compare the Silymarin, as traditional treatment with mesenchymal stem cell conditioned medium (MSC-CM), as a novel strategy, both with therapeutic potentialities in term of liver failure (LF) treatment.
Mice models with liver failure were induced with CCl and were treated in the groups as follows: normal mice receiving DMEM-LG medium as control, LF-mice receiving DMEM-LG medium as sham, LF-mice receiving Silymarin as LF-SM, and LF-mice receiving MSC sphere CM as LF-MSC-CM. Biochemical, histopathological, molecular and protein level parameters were evaluated using blood and liver samples. Liver enzymes, MicroRNA-122 values as well as necrotic score were significantly lower in the LF-SM and LF-MSC-CM groups compared to sham. LF-SM showed significantly higher level of total antioxidant capacity and malondialdehyde than that of LF-MSC-CM groups. Sph-MSC-CM not only induced more down-regulated expression of fibrinogen-like protein 1 and receptor interacting protein kinases1 but also led to higher expression level of keratinocyte growth factor. LF-MSC-CM showed less mortality rate compared to other groups.
Hepato-protective potentialities of Sph-MSC-CM are comparable to those of Silymarin. More inhibition of necroptosis/ necrosis and inflammation might result in rapid liver repair in case of MSC-CM administration.
常见的肝脏疾病治疗方法未能满足该重要医学领域的所有需求。因此,迫切需要适当的新辅助疗法。间充质干细胞(MSCs)及其衍生物在这方面具有很大的应用潜力。我们旨在比较水飞蓟素(传统治疗方法)和间充质干细胞条件培养基(MSC-CM),作为一种新策略,在治疗肝衰竭(LF)方面都具有治疗潜力。
用 CCl 诱导肝衰竭小鼠模型,并将其分为以下几组进行治疗:正常小鼠用 DMEM-LG 培养基作为对照(NC),肝衰竭小鼠用 DMEM-LG 培养基作为假手术(Sham),肝衰竭小鼠用水飞蓟素治疗(LF-SM),肝衰竭小鼠用 MSC 球 CM 治疗(LF-MSC-CM)。用血液和肝脏样本评估生化、组织病理学、分子和蛋白水平参数。与 Sham 组相比,LF-SM 和 LF-MSC-CM 组的肝酶、miR-122 值和坏死评分显著降低。LF-SM 组的总抗氧化能力和丙二醛水平明显高于 LF-MSC-CM 组。Sph-MSC-CM 不仅诱导纤维蛋白原样蛋白 1 和受体相互作用蛋白激酶 1 的下调表达更高,而且还导致角质细胞生长因子的表达水平更高。与其他组相比,LF-MSC-CM 组的死亡率较低。
Sph-MSC-CM 的肝保护潜力与水飞蓟素相当。MSC-CM 给药可能会导致更少的坏死/坏死和炎症,从而更快地修复肝脏。